Inozyme Pharma Higher on Positive Ongoing Phase 1/2 Trial Topline Data

(24/7 MARKET NEWS) – Inozyme Pharma, Inc. (Nasdaq:INZY) reported, this morning, positive topline pharmacokinetic (PK), pharmacodynamic (PD), and safety data from the ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE), as well as encouraging patient reported outcome data as measured by global impression of change (GIC) in the ENPP1 Deficiency trial.

Inozyme Pharma is at $2.69, up $0.47 (+21.17%), on trading volume of 1 million premarket shares.

Its 52-week trading range is $0.991 to $7.03. If it can break through its recent $3 high, its setup is favorable to potentially challenge the $4+ level.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.